Recently, the Centers for Disease Control and Prevention (CDC) issued updated “Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States.” The information is located here: https://www.cdc.gov/vaccines/covid-19/info-byproduct/clinical-considerations.html  Under the section titled “Laboratory Reporting,” the CDC provided recommendations about the timing of the administration of the mRNA COVID-19 vaccine and Tuberculosis (TB) testing products.  See full letter here.

Questions?

Contact:

Laura Hofmann, MSN, RN – Director of Clinical and Nursing Facility Regulatory Services
c: 425-231-4804